Stock Watch: Q2 Earnings Shelter Novartis From Recent Storms

But Entresto’s Success Is Double-Edged

 
• By Andy Smith

Novartis’s positive start to second-quarter earnings season also made more acute the potential impact of the recent invalidation of the patent on its biggest product.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business